SS-31 Dosage Protocol: What Research and Early Trials Show

There is no single official SS-31 dosage protocol, because SS-31 (elamipretide) is not an approved drug. Published human trials most often used 40 mg subcutaneously once daily, while earlier infusion studies used weight-based intravenous dosing and animal studies typically used 1–5 mg/kg per day. Community protocols reported online range from about 2.5 mg to 10 mg daily, but those numbers do not carry the same evidence as a controlled trial.

What SS-31 Is and Why a Standard Dose Does Not Exist

SS-31, also called elamipretide or MTP-131, is a small tetrapeptide that targets cardiolipin on the inner mitochondrial membrane. Researchers study it in mitochondrial myopathy, Barth syndrome, heart failure, and eye conditions such as dry age-related macular degeneration.

No regulatory agency has approved elamipretide for human use, so there is no product label, no approved indication, and no standard dosing schedule. Every number discussed below comes from a research context, and each context carries different limitations.

Doses Reported in Human Clinical Trials

Clinical trials provide the most structured SS-31 dosing data available. Doses are fixed in advance, administered under supervision, and reported publicly, which makes them the closest thing to a reference point.

Trial setting	Route	Reported dose	Frequency
Barth syndrome	Subcutaneous	40 mg	Once daily
Primary mitochondrial myopathy	Subcutaneous	40 mg	Once daily
Heart failure and cardiac surgery	Intravenous infusion	0.05–0.25 mg/kg per hour	Short infusions
Ophthalmology research	Topical eye drop	5 mg/mL formulations	Once daily

Trial results have been mixed. Elamipretide has produced signals on some functional endpoints, but regulators have not accepted those results as proof of benefit, and a marketing application for Barth syndrome received a complete response letter from the FDA.

Doses Used in Animal Research

Rodent studies most commonly use 1–5 mg/kg per day, with 3 mg/kg appearing frequently in cardiac, kidney, and skeletal muscle models. Doses in that range are usually injected subcutaneously or intraperitoneally, and some protocols split the daily amount into two administrations.

Animal doses of SS-31 do not convert directly into human doses. Species differences in metabolism, body-surface-area scaling, and the use of induced disease models all limit how far those numbers can be carried over.

How Community Protocols Compare With Trial Doses

Self-reported protocols are the least reliable source of SS-31 dosing information, but they are also the most common one people encounter. Community summaries, including ss-31 dosage reddit threads and podcast write-ups such as ss-31 dosage jay campbell, usually land between 2.5 mg and 10 mg per day.

Source	Typical daily amount	Frequency	Reliability
Human clinical trials	40 mg subcutaneous	Once daily	Monitored and published
Animal studies	1–5 mg/kg	Once or split daily	Preclinical only
Community reports	2.5–10 mg	Once or split daily	Unverified

A reported ss-31 peptide injection dosage found on a forum is not evidence of safety or effectiveness. Those figures are self-reported, frequently copied between threads, and rarely tied to a documented outcome.

Search interest in ss 31 peptide dosage has grown faster than the published evidence behind it. Any ss 31 dosage pulled from a forum should be treated as anecdotal until it appears in a controlled study.

SS-31 Reconstitution and Injection Math

Any discussion of ss-31 reconstitution and dosage comes down to one calculation: total milligrams of peptide divided by total milliliters of diluent.

Vial size	Diluent added	Concentration	Volume for a 5 mg dose
5 mg	1 mL	5 mg/mL	1.0 mL
10 mg	1 mL	10 mg/mL	0.5 mL
10 mg	2 mL	5 mg/mL	1.0 mL
10 mg	5 mL	2 mg/mL	2.5 mL

Most researchers use bacteriostatic water, add it slowly down the vial wall, and swirl rather than shake to avoid foaming. Reconstituted peptide is typically refrigerated and used within a few weeks.

A common community ss-31 dosing protocol calls for a single morning injection, but no trial data confirms that injection timing changes anything for this peptide.

Timing, Cycle Length, and Storage

Clinical protocols used once-daily dosing for 4 to 12 weeks, depending on the indication. Longer human exposure data is limited, so cycle length in community use remains largely guesswork.

• Frequency: once daily in most reported protocols.
• Timing: morning injections are common; no comparative data supports a specific time of day.
• Storage: lyophilized powder stays frozen, while reconstituted vials go in the refrigerator.
• Handling: avoid repeated freeze-thaw cycles and keep the peptide protected from light.

Safety and Legal Status

SS-31 is not FDA-approved for human use in the United States.

Products sold online are therefore research chemicals rather than regulated medicines. Purity, sterility, and actual peptide content are not guaranteed by any oversight body.

In trials, the most frequently reported side effects were injection site reactions; other events varied by population and were generally described as mild to moderate. Small studies cannot rule out uncommon or delayed risks.

Anyone considering SS-31 or a related compound should speak with a licensed healthcare professional first. This article is informational and is not medical advice.

COMMON QUESTIONS

Frequently Asked Questions

What SS-31 dosage protocol was used in clinical trials?

Most human trials of elamipretide used 40 mg injected subcutaneously once daily, while earlier heart failure studies used intravenous infusions of roughly 0.05–0.25 mg/kg per hour. Trial protocols ran for about 4 to 12 weeks depending on the indication. SS-31 is not FDA-approved, so none of these regimens represents an official standard dose.

How do you reconstitute SS-31 for injection?

Reconstitution depends on the vial size and the concentration you want. A 10 mg vial mixed with 2 mL of bacteriostatic water yields 5 mg/mL, so a 5 mg dose equals 1 mL. Add the water slowly down the vial wall, swirl instead of shaking, and refrigerate the reconstituted vial.

Is SS-31 FDA-approved or legal to buy in the United States?

SS-31 (elamipretide) is not FDA-approved for any human use in the United States. It is sold online as a research chemical, which means it is not regulated as a medicine and its purity and sterility are not verified. Buying a research chemical does not make it safe or legal to use in humans.